Thomas Kapsner has been serving as CEO of Morphochem AG, a 100% subsidiary of Biovertis AG, Vienna, since 2008. He is also the CEO of Biovertis which he joined in 2006.
His previous position was Managing Director at Kapsner & Schmid GmbH, a European corporate finance advisory firm focusing on healthcare and life sciences. During that time, he also held several management and executive positions at client companies in challenging start-up and turn-around situations. Before that he was an investment manager with GE Capital, a consultant with McKinsey & Company, and co-founder and Managing Director of the Bavarian Public Health Research Center in Munich, Germany.
Dr. Kapsner holds a medical degree from the University of Munich. He was a research fellow at the university’s Department of Internal Medicine and its Department of Medical Informatics, Biometry and Epidemiology.